BSX

SEC source: 0001225208-23-008245 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,032

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

SEC source: 0001225208-23-007928 · doc4.xml · derivative · entry 3

Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,180

Underlying: Common Stock · 1,090 shares

Expires 2025-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant.

SEC source: 0001225208-23-007928 · doc4.xml · nonDerivative · entry 2

Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,874

SEC source: 0001225208-23-007928 · doc4.xml · nonDerivative · entry 1

Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,361

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-23-007574 · doc4.xml · derivative · entry 5

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,799

Underlying: Common Stock · 2,960 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.

SEC source: 0001225208-23-007574 · doc4.xml · derivative · entry 4

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,242

Underlying: Common Stock · 3,448 shares

Expires 2025-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.

SEC source: 0001225208-23-007574 · doc4.xml · nonDerivative · entry 3

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,584

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $52.59 to $53.17, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-23-007574 · doc4.xml · nonDerivative · entry 2

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,255

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

SEC source: 0001225208-23-007574 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

SEC source: 0001225208-23-007373 · doc4.xml · derivative · entry 4

Morano Susan E · CIK 0001983791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,082

Underlying: Common Stock · 456 shares

Expires not disclosed

F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F5 · shares: Grant of deferred stock units in lieu of 25% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,428.87 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $115,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F5 · derivative.exercise_date: Grant of deferred stock units in lieu of 25% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,428.87 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $115,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F5 · derivative.expiration_date: Grant of deferred stock units in lieu of 25% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,428.87 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $115,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-23-007373 · doc4.xml · derivative · entry 3

Morano Susan E · CIK 0001983791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,626

Underlying: Common Stock · 1,626 shares

Expires not disclosed

F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · shares: Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $87,094.25 (representing 50% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $205,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F4 · derivative.exercise_date: Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $87,094.25 (representing 50% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $205,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F4 · derivative.expiration_date: Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $87,094.25 (representing 50% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $205,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-23-007373 · doc4.xml · nonDerivative · entry 2

Morano Susan E · CIK 0001983791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,082

F2 · price: Grant of restricted stock in lieu of 25% yearly cash compensation, following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. Reflects a value of approximately $24,428.88 (representing 25% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $115,000) divided by the closing price of the common stock on the date of grant.

SEC source: 0001225208-23-007373 · doc4.xml · nonDerivative · entry 1

Morano Susan E · CIK 0001983791 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,626

F1 · price: Grant of restricted stock to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of restricted stock vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $87,094.25 (representing 50% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $205,000) divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-23-007372 · doc4.xml · nonDerivative · entry 1

Mega Jessica L · CIK 0001793582 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,253

F1 · price: Grant of restricted stock to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2024 annual meeting of stockholders. The grant of restricted stock vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $174,188.50 (representing the prorated amount of the non-employee director compensation program's annual equity award having a value of $205,000) divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-23-007118 · doc4.xml · derivative · entry 3

Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 729 shares

Expires 2023-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2020, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2020, the first anniversary of the date of grant.

SEC source: 0001225208-23-007118 · doc4.xml · nonDerivative · entry 2

Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,271

SEC source: 0001225208-23-007118 · doc4.xml · nonDerivative · entry 1

Monson Jonathan · CIK 0001779170 · SVP, Global Controller and CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-23-007117 · doc4.xml · derivative · entry 3

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,072

Underlying: Common Stock · 4,036 shares

Expires 2025-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant.

SEC source: 0001225208-23-007117 · doc4.xml · nonDerivative · entry 2

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,328

SEC source: 0001225208-23-007117 · doc4.xml · nonDerivative · entry 1

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,687

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-23-006969 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,453

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 21, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $53.61 to $53.95, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-23-006849 · doc4.xml · derivative · entry 5

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,759

Underlying: Common Stock · 2,960 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.

SEC source: 0001225208-23-006849 · doc4.xml · derivative · entry 4

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,690

Underlying: Common Stock · 3,448 shares

Expires 2025-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.

SEC source: 0001225208-23-006849 · doc4.xml · nonDerivative · entry 3

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,847

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $52.95 to $53.52, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-23-006849 · doc4.xml · nonDerivative · entry 2

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,518

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

SEC source: 0001225208-23-006849 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

SEC source: 0001225208-23-006012 · doc4.xml · derivative · entry 5

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 56,921 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 15, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.

SEC source: 0001225208-23-006012 · doc4.xml · nonDerivative · entry 2

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,859

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 15, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $53.37 to $53.80, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-23-006012 · doc4.xml · nonDerivative · entry 1

Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,198

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 15, 2023, intended to comply with the prior version of Rule 10b5-1(c).

SEC source: 0001225208-23-006011 · doc4.xml · derivative · entry 5

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,719

Underlying: Common Stock · 2,960 shares

Expires 2024-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.

SEC source: 0001225208-23-006011 · doc4.xml · derivative · entry 4

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,138

Underlying: Common Stock · 3,448 shares

Expires 2025-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.

SEC source: 0001225208-23-006011 · doc4.xml · nonDerivative · entry 3

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,110

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $53.37 to $53.661, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-23-006011 · doc4.xml · nonDerivative · entry 2

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,781

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

SEC source: 0001225208-23-006011 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,821

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 9, 2023, intended to comply with the prior version of Rule 10b5-1(c).

SEC source: 0001225208-23-005471 · doc4.xml · nonDerivative · entry 1

WICHMANN DAVID S · CIK 0001268489 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,600

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-23-005470 · doc4.xml · nonDerivative · entry 1

Sununu John E · CIK 0001458974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,741

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-23-005472 · doc4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,629

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-23-005469 · doc4.xml · nonDerivative · entry 1

ROUX DAVID J · CIK 0001234273 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,591

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-23-005466 · doc4.xml · nonDerivative · entry 1

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,025

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-23-005468 · doc4.xml · derivative · entry 2

LUDWIG EDWARD J · CIK 0001221783 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,366

Underlying: Common Stock · 2,984 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · shares: Reflects a value of $155,000 divided by the closing price of common stock on the date of grant.

F5 · derivative.exercise_date: Deferred stock units were granted in lieu of quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F5 · derivative.expiration_date: Deferred stock units were granted in lieu of quarterly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-23-005468 · doc4.xml · derivative · entry 1

LUDWIG EDWARD J · CIK 0001221783 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,382

Underlying: Common Stock · 3,946 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · shares: Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-23-005467 · doc4.xml · derivative · entry 1

FUJIMORI YOSHIAKI · CIK 0001233160 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,697

Underlying: Common Stock · 3,946 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · shares: Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

SEC source: 0001225208-23-005464 · doc4.xml · nonDerivative · entry 1

Connors Nelda J · CIK 0001478748 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,823

F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $205,000 divided by the closing price of common stock on the date of grant.

SEC source: 0001225208-23-005386 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,611

Underlying: Common Stock · 4,203 shares

Expires 2026-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

SEC source: 0001225208-23-005386 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,689

SEC source: 0001225208-23-005386 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,606

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-23-005385 · doc4.xml · derivative · entry 4

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,306

Underlying: Common Stock · 2,101 shares

Expires 2026-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

SEC source: 0001225208-23-005385 · doc4.xml · nonDerivative · entry 2

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,150

SEC source: 0001225208-23-005385 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,082

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-23-005384 · doc4.xml · derivative · entry 3

Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,688 shares

Expires 2024-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant.